NovaBridge Biosciences · NASDAQ:NBP
NovaBridge Biosciences — I-Mab — H1 2024 Earnings Presentation
23 slides from NovaBridge Biosciences's earnings presentation, Aug 28, 2024
Slide 1: I-Mab Biopharma 1H 2024 Results
Transforming Potential into Reality I-Mab Biopharma 1H 2024 Results August 28, 2024
Slide 2: Disclaimer
Disclaimer Legal Disclaimer. This presentation has been prepared by I-Mab (the “Company”) solely for informational purposes. Certain of the information included herein was obtained from various sources, including certain third parties, and has not been independently verified by the Company. By viewi
Slide 3: Agenda
Agenda CEO Remarks and Introduction, Sean Fu R&D Strategy, Phillip Dennis Closing Remarks, Sean Fu Finance and Transition Update, Joseph Skelton
Slide 4: Significant Progress Towards Becoming a U.S.-Based Biotech
Significant Progress Towards Becoming a U.S.-Based Biotech Completed divestiture of China operations; closed on 04/02/2024 Extinguished ~$200M of redemption obligations and significantly reduced operating expenses; remaining ~$15M of redemption obligations to be settled in Sept-20241 New streamlined
Slide 5: Experienced U.S.-Based Management Team
Experienced U.S.-Based Management Team Sean Fu, PhD, MBA Interim Chief Executive Officer Scientist with 20+ years in pharma focused on early-stage clinical development in targeted therapeutics Previous Leadership Experience Phillip Dennis, MD, PhD Chief Medical Officer Medical oncologist with 20-yea
Slide 6: Pipeline assets and next steps
Asset PHASE 1 PHASE 2 PHASE 3 MARKET OPPORTUNITY STATUS/POTENTIAL NEXT STEPS PARTNERSHIPS Uliledlimab CD73 mAb 1L mNSCLC: Target population of 300k+ patients2 1H 2025: First patient dosed in pembrolizumab + chemo combination for 1L mNSCLC 2H 2025: Phase 2 PFS data from ongoing TJBio study (China-onl
Slide 7: Uliledlimab (targeting CD73)
Uliledlimab (targeting CD73) Initial development focused on 1L mNSCLC with potential to expand across multiple indications in combination with immune checkpoint inhibitors Anti-CD73 CD73 Biology Key Advantages CD73 is the rate-limiting enzyme that converts AMP into immunosuppressive adenosine Uliled
Slide 8: Uliledlimab: A Differentiated CD73 Antibody
CD73 enzyme activity inhibition Dose-dependent CD73 inhibition without the “hook effect” Uliledlimab: A Differentiated CD73 Antibody Open conformation (inactive) Closed conformation (active) Oleclumab1 Intra-dimer binding mode Inter-dimer binding mode Open conformation (inactive) Closed conformation
Slide 9: Uliledlimab + Toripalimab Data Supports Patient Selection and Shows Manageable Toxicity
Safety profile of combination comparable to CPI monotherapy studies Uliledlimab + Toripalimab Data Supports Patient Selection Based on CD73 Expression and Shows Manageable Toxicity Notes: ORR = objective response rate; MTD = maximally tolerated dose; Q3W = every three weeks; AE = adverse events; CPI
Slide 10: Rationale to Support Uliledlimab + Pembro + Chemotherapy in 1L mNSCLC
Rationale to Support Uliledlimab + Pembro + Chemotherapy in 1L mNSCLC Samanta D, Park Y, Ni XH, Semenza G. 2017. Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells. PNAS Vol. 115, No 6. Notes: mNSCLC = metastatic non-small cell lung cancer; IO = I
Slide 11: Uliledlimab Development Plan: Randomized Study Design
Uliledlimab Development Plan: Randomized Study Design for Combination with Pembrolizumab + Chemotherapy Notes: mNSCLC = metastatic non-small cell lung cancer; R = randomized; ECOG PS = ECOG Performance Status Scale; TPS = tumor proportion score; ORR = objective response rate; PFS = progression free
Slide 12: Anticipated Milestones for Uliledlimab and the Adenosine Pathway
Anticipated Milestones for Uliledlimab and the Adenosine Pathway Source: Company filings, Wall Street Equity Research; Clinicaltrials.gov Notes: PFS = progression free survival; Pembro = pembrolizumab; Uli = uliledlimab; Chemo = chemotherapy; Tori = toripalimab Uliledlimab Adenosine Pathway 2H 2025
Slide 13: Givastomig Molecular Design and Key Differentiation
Molecular Design Key Differentiation Binding activity demonstrated across various levels of CLDN18.2 expression Exhibits CLDN18.2 binding even on low expressing tumor cells Higher-affinity binding to CLDN18.2 compared to reference antibody Zolbetuximab Localized T cell activation in TME to minimize
Slide 14: Unique Design to Enable Potential Wide Use Plus Favorable Initial Safety Profile
Unique Design to Enable Potential Wide Use Plus Favorable Initial Safety Profile Encouraging Responses in Previously Treated Patients, Including Those with Low CLDN18.2 Expression Levels Dose Expansion Data and New Nivolumab + Chemotherapy Combo Study Ongoing Unique Bispecific Design Properties and
Slide 15: Givastomig Yields Better Monotherapy Responses Compared to Zolbetuximab
Givastomig Yields Better Monotherapy Responses in Patients with Low to High CLDN18.2 Expression Compared to Phase 1/2 Zolbetuximab Studies Drug Givastomig (bi-specific) Zolbetuximab (mAb) Phase Phase 1 Phase 1 Phase 2 CLDN18.2 – Expression of the Study Group IHC ≥1+ in ≥1% cells IHC ≥1+ in ≥1% cells
Slide 16: Ragistomig Molecular Design
Molecular Design Target Drug Profile Molecule binds to PD-L1 to inhibit PD-1/PD-L1 interaction Targeting PD-L1+ tumor cells Blocking PD-L1/PD-1 immune inhibitory signaling PD-L1-dependent 4-1BB activation at the tumor site Potent tumor-directed 4-1BB activation to enhance anti-tumor immunity Enhance
Slide 17: Phase 1 Data Support Further Development as Monotherapy and in Combination
Phase 1 Data Support Further Development as a Monotherapy and in Combination with Other Agents Overview: 44 efficacy evaluable patients (53 enrolled) with advanced or relapsed/refractory solid tumors (NCT04762641) 64.2% (34/53) of patients enrolled had at least three prior lines of systemic anti-can
Slide 18: Manageable Safety Profile
Manageable Safety Profile MTD established with 7 mg/kg every two-week dosing Most common TRAEs were increased ALT and increased AST None of the transaminase elevations were accompanied by clinically significant, treatment-related bilirubin increases Grade ≥ 3 ALT or AST increases occurred in 24.5% (
Slide 19: Pipeline assets and next steps
Asset PHASE 1 PHASE 2 PHASE 3 MARKET OPPORTUNITY STATUS/POTENTIAL NEXT STEPS PARTNERSHIPS Uliledlimab CD73 mAb 1L mNSCLC: Target population of 300k+ patients2 1H 2025: First patient dosed in pembrolizumab + chemo combination for 1L mNSCLC 2H 2025: Phase 2 PFS data from ongoing TJBio study (China-onl
Slide 20: Strong Corporate Development Progress and Reduction in Expenditures
Strong Corporate Development Progress and Reduction in Expenditures Full-time employees as of 12/31/2023 per the 20-F Full-time employees as of 06/30/2024 Entered into clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with
Slide 21: Pro Forma Cash Reconciliation
Reclassification of cash and cash equivalents at I-Mab Shanghai that subsequently remained with divested entity to settle working capital obligations Outflows incurred during the first quarter of 2024 related to the divestiture of China operations including: $19M Series C investment in TJ Biopharma,
Slide 22: Financial Information and Upcoming Milestones
Assuming the conversion of all ordinary shares into ADSs Notes: CPI = checkpoint inhibitor; CLDN = Claudin; GC = gastric cancers; GEJ = gastroesophageal junction; EAC = esophageal cancer; ESMO 2024 = the European Society for Medical Oncology Annual Meeting in 2024; PFS = progression free survival; O
Slide 23: Stay connected
Stay connected Q&A [email protected] Contact Us